Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Dividends per Share: HK$0.00 (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
8 GF Score
Price HK$3.80
! 3 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co Dividends per Share?

Guangzhou Innogen Pharmaceutical Group Co HKSE:02591 -1.94% 8 Dividends per Share is HK$0.00 as of Dec. 2025. GuruFocus rates HKSE:02591 with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Guangzhou Innogen Pharmaceutical Group Co's dividends per share for the six months ended in Dec. 2025 was HK$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.00. Its Dividend Payout Ratio for the six months ended in Dec. 2025 was 0.00. As of today, Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Guangzhou Innogen Pharmaceutical Group Co  (HKSE:02591) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Guangzhou Innogen Pharmaceutical Group Co's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.54
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co Dividends per Share Related Terms

Guangzhou Innogen Pharmaceutical Group Co Dividends per Share Historical Data

* Premium members only.

The historical data trend for Guangzhou Innogen Pharmaceutical Group Co's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co Dividends per Share Chart

Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend Dec23 Dec24 Dec25
Dividends per Share
0.00 0.00 0.00

Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Dividends per Share 0.00 0.00 0.00 0.00 0.00

HKSE:02591 vs VRTX, REGN, RVMD: Dividends per Share Comparison

For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guangzhou Innogen Pharmaceutical Group Co Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Guangzhou Innogen Pharmaceutical Group Co's Dividend Yield % falls into.


HKSE:02591
8GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
Dividends per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co Dividends per Share Calculation

Dividends paid to per common share.

Frequently Asked Questions Learn more about Dividends per Share →
What does a Dividends per Share of HK$0.00 mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Dividends per Share of HK$0.00 as of Dec. 2025. Dividends per share represents the per-share amount paid as dividends. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors.
Is Guangzhou Innogen Pharmaceutical Group Co's Dividends per Share too high?
Guangzhou Innogen Pharmaceutical Group Co's current Dividends per Share is HK$0.00. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Dividends per Share compare to VRTX and REGN?
Guangzhou Innogen Pharmaceutical Group Co's Dividends per Share of HK$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Biotechnology company?
A good Dividends per Share depends on the Biotechnology industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. Guangzhou Innogen Pharmaceutical Group Co's current Dividends per Share is HK$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Dividends per Share of HK$0.00. The current Dividends per Share is HK$0.00. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Dividends per Share is HK$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
8GF Score

Get the complete analysis for HKSE:02591

Dividends per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.80
Price